Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare Biotechnology

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Says Barda 25 Million Funding on the New Website

<< Previous

Bullboard Posts

Next >>

Comment by Moonshiner592on Feb 06, 2021 2:20pm

112 Views

Post# 32493507

RE:RE:Says Barda 25 Million Funding on the New Website

Moonshiner592 wrote:

Chritters wrote: Says on the website they have a 25 Million cash from Barda so if they got funding. Were in the money

Indeed!! That's what caught my undivided attention!!

That's good stuff! ... Company credibility will be nicely restored!!

Go Kaly!! GO!!!